FindTrial
Sign In

Abiraterone Oral Tablet

DRUG2 trials

Sponsors

Karolinska Institutet, University of Chicago

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Prostate AdenocarcinomaProstate CancerProstate Cancer MetastaticProstate Neoplasm

Phase 1

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
TerminatedNCT05276492
University of ChicagoProstate Adenocarcinoma, Prostate Cancer, Prostate Cancer Metastatic +1
Start: 2023-01-24End: 2024-11-16Updated: 2025-10-03

Phase 3

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
RecruitingNCT03903835
Karolinska InstitutetMetastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Start: 2019-02-01End: 2026-12-31Target: 750Updated: 2025-04-09

Related Papers

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.
2025-04-213 citations
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
Nature Medicine2024-08-2018 citations
Generally Speaking Survival of Men with Metachronous Metastatic Hormone-Touchy Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Zenodo (CERN European Organization for Nuclear Research)2022-03-18
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.
2020-06-2623 citations